HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Professor Pravin Kaumaya

Dr Kaumaya is Prof of Medicine in the Department of Obstetric Gynecology at Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center.  He is an expert in the fields of vaccine research with an emphasis on peptide vaccines for cancer.

The Kaumaya laboratory investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells.  Novel treatments that combine both prophylactic and immunotherapeutic approaches as well as integrating preclinical and clinical research for the benefits of the cancer patients have been developed. The vaccines target breast, ovarian, lung, pancreatic and colon cancers. Their immune intervention strategies are based on the hypothesis that the design of unique peptides which can recapitulate the exquisite 3-dimensional structure of the tumor antigen and when combined with a “promiscuous” T cell activating species generate vaccine candidates.

Dr Kaumaya has published over 130 peer-reviewed articles in major scientific journals and is a Fellow of the American Association for the Advancement of Science (AAAS).

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551